{
    "organizations": [],
    "uuid": "ef65d624444d39b6553794e76546835a585d1379",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cyteir-therapeutics-secures-29-mln/brief-cyteir-therapeutics-secures-29-mln-series-b-to-advance-novel-molecularly-targeted-therapies-for-cancer-and-autoimmune-diseases-idUSASB0C9EC",
    "ord_in_thread": 0,
    "title": "BRIEF-Cyteir Therapeutics Secures $29 Mln Series B To Advance Novel, Molecularly Targeted Therapies For Cancer And Autoimmune Diseases",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Celgene Corp:\n* CYTEIR THERAPEUTICS SECURES $29 MILLION SERIES B TO ADVANCE NOVEL, MOLECULARLY TARGETED THERAPIES FOR CANCER AND AUTOIMMUNE DISEASES\n* CYTEIR THERAPEUTICS - ANNOUNCED CLOSE OF A $29 MILLION SERIES B PREFERRED STOCK FINANCING Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T20:17:00.000+02:00",
    "crawled": "2018-03-09T14:36:07.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "celgene",
        "corp",
        "cyteir",
        "therapeutic",
        "secures",
        "million",
        "series",
        "b",
        "advance",
        "novel",
        "molecularly",
        "targeted",
        "therapy",
        "cancer",
        "autoimmune",
        "disease",
        "cyteir",
        "therapeutic",
        "announced",
        "close",
        "million",
        "series",
        "b",
        "preferred",
        "stock",
        "financing",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}